Interaction of epitopic missense variants of VEGFA with therapeutic monoclonal antibodies

Interaction of epitopic missense variants of VEGFA with therapeutic monoclonal antibodies

Vascular Endothelial Growth Factor A (VEGFA) is a glycoprotein that mediates various biological processes, including angiogenesis, vascular permeability, and cellular migration. Aberrant VEGFA signaling is also one of the hallmarks of many types of cancer and has been implicated in various ophthalmo...

Full description

Bibliographic Details
Main Authors:	Md Tamzid Hossain Tanim, Sabrina Samad Shoily, Tamim Ahsan, Kaniz Fatema, Sarah Umaymah Mahdiyah, Abu Ashfaqur Sajib
Format:	Article
Language:	English
Published:	Bangladesh Society for Microbiology, Immunology, and Advanced Biotechnology 2023-08-01
Series:	Journal of Advanced Biotechnology and Experimental Therapeutics
Subjects:	vegfa; genetic variants; therapeutic monoclonal antibodies; bevacizumab; ranibizumab
Online Access:	http://www.ejmanager.com/fulltextpdf.php?mno=142715

Similar Items

Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach
by: Chiara Bianca Maria Platania, et al.
Published: (2015-10-01)

Erratum: Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach
by: Science eProduction Office
Published: (2016-06-01)

Common genetic variants and pathways in diabetes and associated complications and vulnerability of populations with different ethnic origins
by: Sabrina Samad Shoily, et al.
Published: (2021-04-01)

Missense variants in the TNFA epitopes and their effects on interaction with therapeutic antibodies—in silico analysis
by: Tamim Ahsan, et al.
Published: (2022-01-01)

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma
by: N. García-Romero, et al.
Published: (2020-06-01)

Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis
by: Xiao-Yu Zhang, et al.
Published: (2014-04-01)

Comparison of Single-Treatment Efficacy of Bevacizumab and Ranibizumab for Retinopathy of Prematurity
by: Fumio Takano, et al.
Published: (2024-07-01)

Comparison of Corneal Endothelial Changes After a Single-Dose Injection of Bevacizumab or Ranibizumab
by: Fatih Horozoğlu, et al.
Published: (2013-12-01)

A comprehensive in silico exploration of the impacts of missense variants on two different conformations of human pirin protein
by: Auroni Semonti Khan, et al.
Published: (2022-07-01)

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
by: Muñoz-Villegas P, et al.
Published: (2021-05-01)

Comparison of the effects of 3 different anti-VEGF drugs on cornea thickness, lens thickness and anterior chamber depth
by: Mehmet Tahir Eski, et al.
Published: (2023-03-01)

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
by: Kiss S, et al.
Published: (2018-08-01)

VEGFA Isoforms as Pro-Angiogenic Therapeutics for Cerebrovascular Diseases
by: Amanda Louise White, et al.
Published: (2023-04-01)

THE ROLE OF VEGFA GENE POLYMORPHISM IN DIABETIC FOOT SYNDROME DEVELOPMENT
by: A. V. Rusanov, et al.
Published: (2019-06-01)

VEGFA may be a potential marker of myopic choroidal thickness and vascular density changes
by: Ting Wan, et al.
Published: (2024-09-01)

Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo
by: Zhenhai Zeng, et al.
Published: (2024-07-01)

EFEKTIVITAS-BIAYA PENGGUNAAN BEVACIZUMAB DAN RANIBIZUMAB SEBAGAI ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PADA PASIEN DENGAN GANGGUAN MATA: TINJAUAN SISTEMATIS
by: Nur Sidik Cahyono, et al.
Published: (2024-04-01)

Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)

Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology
by: Jonathan Micieli, et al.
Published: (2020-08-01)

miR-203 Suppresses Tumor Growth and Angiogenesis by Targeting VEGFA in Cervical Cancer
by: Xiangyu Zhu, et al.
Published: (2013-07-01)

Identification of novel somatic fusions of ERG‐VEGFA, TMPRSS2‐ERG, and VEGFA‐TMPRSS2 in prostate cancer treated with anlotinib and androgen deprivation therapy: A case report
by: Qiuli Liu, et al.
Published: (2022-06-01)

Disease-associated metabolic pathways affected by heavy metals and metalloid
by: Zinia Haidar, et al.
Published: (2023-01-01)

Effects of Bevacizumab, an Anti Vascular Endothelial Growth Factor Monoclonal Antibody, on Kidney Function and Morphology
by: Neslihan Soysal Atile, et al.
Published: (2016-04-01)

VEGFA, MYC, and JUN are abnormally elevated in the synovial tissue of patients with advanced osteoarthritis
by: Genxiang Rong, et al.
Published: (2025-01-01)

CircRNA-miRNA-VEGFA: an important pathway to regulate cancer pathogenesis
by: Lei Zhang, et al.
Published: (2023-05-01)

Asiaticoside inhibits breast cancer progression and tumor angiogenesis via YAP1/VEGFA signal pathway
by: Mengmeng Guo, et al.
Published: (2024-09-01)

Fibrotic Changes and Endothelial-to-Mesenchymal Transition Promoted by VEGFR2 Antagonism Alter the Therapeutic Effects of VEGFA Pathway Blockage in a Mouse Model of Choroidal Neovascularization
by: Franco Aparecido Rossato, et al.
Published: (2020-09-01)

Preparation and in vitro characterization of monoclonal antibody ranibizumab conjugated magnetic nanoparticles for ocular drug delivery
by: Neşe Ayata, et al.
Published: (2020-11-01)

The VEGFA gene and anterior cruciate ligament rupture risk in the Caucasian population
by: Ewelina Lulińska-Kuklik, et al.
Published: (2018-10-01)

Hypoxia-autophagy axis induces VEGFA by peritoneal mesothelial cells to promote gastric cancer peritoneal metastasis through an integrin α5-fibronectin pathway
by: Xiaoxun Wang, et al.
Published: (2020-10-01)

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
by: Jing Chen, et al.
Published: (2023-10-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Photodynamic Therapy and Bevacizumab Combination for Polypoidal Choroidal Vasculopathy Refractory to Intravitreal Ranibizumab
by: Zeynep Alkin, et al.
Published: (2016-12-01)

Inflammatory choroidal neovascularization in Indian eyes: Etiology, clinical features, and outcomes to anti-vascular endothelial growth factor
by: Rupak Roy, et al.
Published: (2017-01-01)

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
by: Jay U Sheth, et al.
Published: (2021-01-01)

Current Treatments of Diabetic Macular Edema
by: Wei-Chun Chan, et al.
Published: (2011-12-01)

Immediate sequential bilateral intravitreal injections: an Indian perspective
by: Tripathy K
Published: (2017-04-01)

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
by: Lin CJ, et al.
Published: (2016-07-01)

Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema
by: Joel Hanhart, et al.
Published: (2015-02-01)

VEGFA contributes to tumor property of glioblastoma cells by promoting differentiation of myeloid-derived suppressor cells
by: Yanlong Tian, et al.
Published: (2024-08-01)